Novo Nordisk AS
(OCSE:NOVO B)
kr
775.8
18.5 (2.44%)
Market Cap: 3.45 Til
Enterprise Value: 3.43 Til
PE Ratio: 36.59
PB Ratio: 28.65
GF Score: 97/100 - Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S Virtual R&D Investor Presentation Transcript
Jun 19, 2020 / 01:00PM GMT
Release Date Price:
kr224.65
(+2.47%)
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board
Presentation
Jun 19, 2020 / 01:00PM GMT
=====================
Corporate Participants
=====================
* Karsten Munk Knudsen
Novo Nordisk A/S - Executive VP, CFO & Member of the Management Board
* Mads Krogsgaard Thomsen
Novo Nordisk A/S - Executive VP, Chief Scientific Officer & Member of the Management Board
* Marcus Schindler
Novo Nordisk A/S - SVP of Global Drug Discovery
* Martin Holst Lange
Novo Nordisk A/S - SVP of Global Development
=====================
- /- -
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot